Viewing nowCombinationEmpagliflozin and Metformin Extended-Release Tablets 25/1000 mg
Empagliflozin 25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.

MFDS item code 202500098 · Approved 2025.01.13 · Insurance code 645907570
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used to improve blood glucose control in adults with type 2 diabetes by supporting dietary and exercise regimens. It is particularly effective for patients whose blood glucose levels are not adequately controlled, and should be used cautiously in patients with cardiovascular disease after consulting a specialist. The medication helps to stabilize blood glucose and aids in overall diabetes management.
For antidiabetic therapy, determine the dose of this product based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and extended-release metformin hydrochloride 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this product once daily in the evening with a meal. Take one 10/1000 mg extended-release tablet or one 25/1000 mg extended-release tablet once daily. Patients taking the 5/1000 mg extended-release tablet or 12.5/1000 mg extended-release tablet should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the metformin hydrochloride dose should be increased gradually. To maintain its extended-release properties, swallow this product whole; do not split, crush, grind, or chew it. This product may not dissolve completely and may be excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the medication. If a patient repeatedly reports finding this product in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). ⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medications, such as insulin, the recommended initial total daily dose when taking this product is empagliflozin 10 mg and the patient's current metformin dose. If the patient tolerates empagliflozin 10 mg well but requires additional glycemic control, the dose may be increased to empagliflozin 25 mg. ⦁ Patients switching from combination therapy with empagliflozin and metformin to this product should receive their current doses of empagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, blood glucose control should be closely monitored and the dose adjusted appropriately. ⦁ When this product is administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. (See Precautions for Use, 4. Adverse Reactions and 6. Interactions.) Special populations Renal impairment Because dose adjustment according to renal function is required, assessment of renal function is recommended before starting this product and periodically thereafter. No dose adjustment is required for patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. For patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and have no other condition that may increase the risk of lactic acidosis, this product may be used with adjustment of the metformin hydrochloride dose as follows. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this product. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, discontinue this product immediately. Older adults In patients 75 years of age and older, consider renal function and the risk of volume depletion.
This medication helps to lower blood glucose and is used in diabetes treatment. Serious and rare side effects such as lactic acidosis can occur while taking this medication, so caution is advised. When taking this medication with other diabetes medications, hypoglycemic symptoms may occur, so caution is necessary. It is recommended that patients with poor kidney function or heart problems, as well as those in acute infection or dehydrated states, avoid taking this medication. If surgery is planned or diagnostic tests involving contrast media will be performed, the medication should be discontinued for a certain period. Pregnant or nursing women should not use this medication. Elderly patients or those with impaired kidney function need to have their dose adjusted and kidney function monitored regularly. This medication can affect the body's fluid balance, so caution is required in cases of dehydration or potential fluid loss. During treatment, genital infections or urinary tract infections may occur, so consulting healthcare professionals immediately if symptoms arise is essential. Long-term use may lower vitamin B12 levels, so regular monitoring of vitamin levels is necessary. Alcohol consumption may increase the risk of lactic acidosis, so it is advisable to avoid drinking during treatment. During medication, monitor for symptoms of hypoglycemia and take appropriate actions immediately if they occur. Do not crush or chew the tablets; swallow them whole, and the tablet coating may appear in the stool, which is normal.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly closed container to protect it from air and moisture. It is important to maintain a storage temperature between 1°C and 30°C at room temperature to ensure the medication's efficacy over time.
White and light pink double convex oval-shaped extended-release film-coated tablets
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationEmpagliflozin 25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.